is retatrutide dangerous and the Grey Market: Buyer Beware – Sarah Hormachea Toxicity linked to unapproved peptide
Description
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes
Color: The liquid should be clear and colorless
This isnt something to DIY.
In the most recent Phase 3 trial (TRIUMPH-4, December 2025), Retatrutide at 12 mg produced 28.7% average weight loss over 68 weeks, translating to roughly 71 pounds lost for the average participant
Your doctor can confirm your BMI and health conditions
References & Sources
